Beijing Succeeder Technology Inc (688338) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Succeeder Technology Inc (688338) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.97 Million ≈ $2.04 Million USD) by net assets (CN¥1.66 Billion ≈ $243.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Beijing Succeeder Technology Inc (688338) market capitalisation for the company's overall valuation and market capitalisation.
Beijing Succeeder Technology Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Beijing Succeeder Technology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beijing Succeeder Technology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Succeeder Technology Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Beijing Succeeder Technology Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greenlight Capital Re Ltd
NASDAQ:GLRE
|
0.045x |
|
Zhanjiang Guolian Aquatic Products
SHE:300094
|
0.160x |
|
Autolus Therapeutics Ltd
NASDAQ:AUTL
|
-0.335x |
|
GREENLIGHT CAP.RE A DL-01
F:G8L
|
0.050x |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
-0.080x |
|
LUBAWA SA
WAR:LBW
|
0.058x |
|
Ginkgo Bioworks Holdings
NYSE:DNA
|
-0.110x |
|
Jiangsu Changqing Agrochemical Co Ltd
SHE:002391
|
0.055x |
Annual Cash Flow Conversion Efficiency for Beijing Succeeder Technology Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Beijing Succeeder Technology Inc from 2016 to 2025. View Beijing Succeeder Technology Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.69 Billion ≈ $247.25 Million |
CN¥79.40 Million ≈ $11.62 Million |
0.047x | -37.10% |
| 2024-12-31 | CN¥1.65 Billion ≈ $240.89 Million |
CN¥122.98 Million ≈ $18.00 Million |
0.075x | +9.04% |
| 2023-12-31 | CN¥1.60 Billion ≈ $234.16 Million |
CN¥109.64 Million ≈ $16.04 Million |
0.069x | +2.52% |
| 2022-12-31 | CN¥1.50 Billion ≈ $220.16 Million |
CN¥100.56 Million ≈ $14.71 Million |
0.067x | -11.60% |
| 2021-12-31 | CN¥1.42 Billion ≈ $207.92 Million |
CN¥107.42 Million ≈ $15.72 Million |
0.076x | +41.88% |
| 2020-12-31 | CN¥1.36 Billion ≈ $198.45 Million |
CN¥72.27 Million ≈ $10.57 Million |
0.053x | -67.24% |
| 2019-12-31 | CN¥374.69 Million ≈ $54.83 Million |
CN¥60.94 Million ≈ $8.92 Million |
0.163x | -45.28% |
| 2018-12-31 | CN¥195.65 Million ≈ $28.63 Million |
CN¥58.15 Million ≈ $8.51 Million |
0.297x | +30.33% |
| 2017-12-31 | CN¥143.30 Million ≈ $20.97 Million |
CN¥32.68 Million ≈ $4.78 Million |
0.228x | -32.88% |
| 2016-12-31 | CN¥103.89 Million ≈ $15.20 Million |
CN¥35.30 Million ≈ $5.17 Million |
0.340x | -- |
About Beijing Succeeder Technology Inc
Beijing Succeeder Technology Inc. engages in the research, development, production, and sales of testing instruments, reagents, and consumables in the field of in vitro diagnostics for thrombosis and hemostasis in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation rate and hematocrit testers, platelet aggregation testers, blood rheol… Read more